![Susan Jones](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Susan Jones
Director Técnico/Científico/I+D en ImmuRx, Inc. .
Fortuna: 315 801 $ al 31/05/2024
Origen de la red de primer grado Susan Jones.
Entidad | Tipo de entidad | Industria | |
---|---|---|---|
Subsidiary | Biotechnology | 17 | |
Tourmaline Bio, Inc.
![]() Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million.
11
| Subsidiary | Miscellaneous Commercial Services | 11 |
ImmuRx, Inc.
![]() ImmuRx, Inc. BiotechnologyHealth Technology ImmuRx, Inc. develops adjuvant platforms for the treatment of cancer and infectious disease. Its product includes CD40 compound, an antibody. The company was founded by Randolph J. Noelle and Ross Kedl in 2005 and is headquartered in Lebanon, NH.
6
| Private Company | Biotechnology | 6 |
Gene Solutions LLC
![]() Gene Solutions LLC BiotechnologyHealth Technology Gene Solutions LLC conducts therapeutic drug discovery research for central nervous system diseases by utilizing its proprietary mitochondrial genomic targets. It delivers mitochondrial therapeutic solutions and choices for pharmaceutical and biotechnology companies to enhance their drug pipelines in the field of Alzheimer’s, Parkinson’s, and schizophrenia diseases. The company was founded in 2006 by William Davis Parker Jr. and Edward P Connell and is headquartered in Charlottesville, VA.
6
| Private Company | Biotechnology | 6 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Susan Jones a través de su red personal
Empresa | Sector | Personas relacionadas | Puesto principal |
---|---|---|---|
AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Director of Finance/CFO Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
The University of California, San Francisco | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Corporate Officer/Principal | |
Harvard College | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
Swarthmore College | College/University | Undergraduate Degree Undergraduate Degree | |
Amphivena Therapeutics, Inc.
![]() Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Drugstore Chains | Founder Director/Board Member | |
ASTERIAS BIOTHERAPEUTICS INC | Biotechnology | Director of Finance/CFO Comptroller/Controller/Auditor | |
Biotechnology Innovation Organization
![]() Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
Dartmouth College | College/University | Undergraduate Degree Undergraduate Degree | |
Maverick Therapeutics, Inc.
![]() Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | Biotechnology | Founder Founder | |
ZURA BIO LIMITED | Biotechnology | Director/Board Member Director/Board Member | |
WEREWOLF THERAPEUTICS, INC. | Pharmaceuticals: Major | Founder Founder | |
RAPTOR PHARMACEUTICAL CORP | Pharmaceuticals: Major | Director of Finance/CFO Director of Finance/CFO | |
IMMUNOVANT, INC. | Biotechnology | General Counsel Chief Operating Officer | |
TURMERIC ACQUISITION CORP. | Financial Conglomerates | Chief Executive Officer Director/Board Member | |
DYNAVAX TECHNOLOGIES CORPORATION | Biotechnology | Director/Board Member Chairman | |
Umoja Biopharma, Inc.
![]() Umoja Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Umoja Biopharma, Inc. engages in the development of immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. It offers an integrated cellular immunotherapy platform comprising VivoVec in vivo delivery, RACR/CAR synthetic receptor payload and TumorTag targeting technologies that attack cancer cells. The company was founded by Michael Jensen, Philip Low, Andy Scharenberg and Ryan Crisman and is headquartered in Seattle, WA. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Alumis, Inc.
![]() Alumis, Inc. Pharmaceuticals: MajorHealth Technology Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Bay City Capital LLC
![]() Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States. | Investment Managers | Corporate Officer/Principal Corporate Officer/Principal | |
SEAGEN INC. | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
Kellogg School of Management | College/University | Masters Business Admin Masters Business Admin | |
Harvard University
![]() Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Corporate Officer/Principal Undergraduate Degree | |
MPM BioImpact, Inc
![]() MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Founder Private Equity Investor | |
Massachusetts Institute of Technology | College/University | Corporate Officer/Principal Graduate Degree | |
Harvard T.H. Chan School of Public Health | College/University | Graduate Degree Graduate Degree | |
UCB | Pharmaceuticals: Major | Chief Operating Officer Corporate Officer/Principal | |
Harvard Medical School | College/University | Doctorate Degree Doctorate Degree | |
ReCode Therapeutics, Inc.
![]() ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO | |
Ludwig-Maximilians-Universität München | College/University | Doctorate Degree Undergraduate Degree | |
Rainier Therapeutics, Inc.
![]() Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Biotechnology | Director of Finance/CFO Chief Executive Officer | |
DYAX CORP. | Pharmaceuticals: Major | President Corporate Officer/Principal | |
VIRIDIAN THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
Ironshore Therapeutics, Inc.
![]() Ironshore Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ironshore Therapeutics, Inc. operates as a pharmaceutical company. The firm offers HLD-200, HLD-900, the morning routine and the delexis products. It develops commercialization of a proprietary drug delivery system. The company was founded by David Gordon MacLeod Lickrish in 2008 and is headquartered in Toronto, Canada. | Pharmaceuticals: Major | Chairman | |
SENSORION | Pharmaceuticals: Major | Chairman | |
TRILLIUM THERAPEUTICS | Biotechnology | Director/Board Member | |
The University of Chicago Booth School of Business | College/University | Masters Business Admin | |
AMAG PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
Braeburn Pharmaceuticals SPRL
![]() Braeburn Pharmaceuticals SPRL Medical SpecialtiesHealth Technology Braeburn Pharmaceuticals SPRL develops and commercializes medical products. It’s a pharmaceutical company focused on novel, long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including addiction, pain, and schizophrenia. The firm offers Probuohine, CAM2038q1w, CAM2038q4w and Risperdone implant. The company was founded in 2012 and is headquartered in Road Town, British Virgin Islands. | Medical Specialties | Corporate Officer/Principal | |
Convergent Therapeutics, Inc.
![]() Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company located in Cambridge, MA. The company focuses on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy (RNT) developed by Dr. Neil Bander, a professor of urologic oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University. The company's lead product candidate, Conv01-?, is a monoclonal antibody conjugated with actinium-225 (225Ac), a radioactive alpha particle emitter, designed to bind to the prostate-specific membrane antigen (PSMA). If FDA-approved, Conv01-? would be the first antibody approved to direct a radioisotope to prostate cancer, and the first drug approved for the use of 225Ac in a cancer treatment. The company was founded by Philip Wayne Kantoff and Neil H. Bander, and Philip Wayne Kantoff has been the CEO since incorporation. | Pharmaceuticals: Major | Chairman | |
Marengo Therapeutics, Inc.
![]() Marengo Therapeutics, Inc. BiotechnologyHealth Technology Marengo Therapeutics, Inc. operates as a biotechnology company that develops immunotherapies. Its product is Universal Targeted Immunotherapy a drug discovery platform that underpins an immunological tumor elimination. The company was founded by Andreas Loew and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
Bausch & Lomb (Australia) Pty Ltd.
![]() Bausch & Lomb (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Bausch & Lomb Australia Pty Ltd. manufactures and distributes prescription medicines. It offers consumer healthcare, prescription, aesthetic skin and eyecare. The company was founded in 2006 and is headquartered in Chatswood, Australia. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Dartmouth Medical School | College/University | Corporate Officer/Principal | |
MIST, Inc.
![]() MIST, Inc. Miscellaneous Commercial ServicesCommercial Services MIST, Inc. is a private company that specializes in the installation, revamp, and routine maintenance of tower internals. The company is based in Pleasant Plain, OH. The company provides an efficient union workforce devoted to safety and successful project completion. The company is committed to teamwork, honesty, hard work, determination, and responsibility. The company has experience working with various industries such as oil refineries, chemical plants, steel mills, and breweries. MIST has recently partnered with Sitedocs to upload all of their safety forms into their platform, making the transition into the digital age. | Miscellaneous Commercial Services | President | |
AVALO THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member |
Estadísticas
Internacional
Estados Unidos | 43 |
Canadá | 3 |
Bélgica | 2 |
Alemania | 2 |
Francia | 2 |
Sectorial
Health Technology | 30 |
Consumer Services | 12 |
Finance | 6 |
Commercial Services | 4 |
Retail Trade | 2 |
Operativa
Director/Board Member | 202 |
Corporate Officer/Principal | 77 |
Independent Dir/Board Member | 70 |
Chairman | 40 |
Founder | 37 |
Las relaciones más conectadas
Insiders | |
---|---|
Luke Evnin | 42 |
Mark McDade | 35 |
Alan Colowick | 30 |
Caley Castelein | 23 |
David Patteson | 22 |
Sapna R. Srivastava | 22 |
Aaron Kantoff | 19 |
Patrick Baeuerle | 19 |
Georgia Erbez | 18 |
Clay Siegall | 18 |
Scott Myers | 18 |
Joanne Viney | 18 |
Julia Eastland | 16 |
W. Middlekauff | 14 |
Natalie Sacks | 13 |
- Bolsa de valores
- Insiders
- Susan Jones
- Conexiones Empresas